GlaxoSmithKline PLC last year received an advance copy of The New England Journal of Medicine's review of Avandia, the drugmaker's experimental diabetes drug, exposing its link to heart attack risks. The leak was a breach of the journal's confidentiality code and could have given Glaxo more time to calculate its response, although the company says it was already consulting with the FDA on the matter. Steven Haffner, the doctor who leaked the review, has said he doesn't know why he did it.

Related Summaries